Yizhen Li presenting her exciting data on PAX5/CD58 mediated blinatomomab resistance in B-ALL. #ASH2022 DM me if you are interested in joining us to work on ALL pharmacogenomics

CONGRESS |#ASH22 Shawn Lee, St. Jude Research highlights results from the drug sensitivity analysis of pediatric ALL subtypes, and its effect on in vivo treatment responses. Pharmacotypes varied widely across subtypes and strongly impacted treatment response and survival outcomes

Today, I sign the Respect for Marriage Act into law – a landmark civil rights bill that honors the courage and sacrifice of generations of couples who fought for marriage equality and equal rights.

Fantastic to see our collaborative studies with Children’s Oncology Group Cancer Center @ CHOP Jun Yang showing the power of large scale integrative genomics and pharmacotyping in ALL highlighted at #ASH22 St. Jude Research

Two amazing studies by St. Jude Research researchers were featured in the Best of ASH22 ASH. Way to go! Petri Pölönen Charles Mullighan Jun Yang

Grateful to be featured on Best of ASH! #ASH22

Strong showing at #ASH22 by St. Jude Research!

Glad to share our recent work on pharmacogenomics of immunotherapy resistance. It is all about leukemia interaction with host T cells! ⁦St. Jude Research⁩ ⁦PGRN⁩ ⁦Science Advances⁩ #blinatumomab ⁦⁦Yizhen Li⁩ science.org/doi/10.1126/sc…

Happy holidays! Introducing RTutor.ai, an AI-powered app that lets you chat with your data in English! RTutor uses Davinci (#ChatGPT’s sibling) to turn requests into R code, which is executed & results are shown instantly, available as a HTML report in seconds. 1/8

To wipe childhood cancer off the map, scientists must chart its genomic landscape. Earlier this year, they created a roadmap of the genetic mutations in acute lymphoblastic leukemia. bit.ly/3CPxefv Charles Mullighan #ResearchWrapUp

Kudos to twitterless Seth Karol and Wenjian Yang, and Keito Hoshitsuki Mary Relling!! The protective effect of TPMT specific to the maintenance phase of ALL therapy (when 6MP was the main drug) was particularly interesting to me. PGRN

In 2022, our scientists advanced research in hemoglobin expression, cancer survivorship, CAR-T, COVID-19, #smFRET and more. We’re writing the next chapter of St. Jude history through their work. ICYMI, explore this year’s accomplishments. stjude.org/research-news #ResearchWrapUp

Scientists from St. Jude performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response. bit.ly/3X4cyId Nature Medicine @junjyang Shawn Lee

Start 2023 with a bang: new paper on ALL pharmacogenomics in Nature Medicine, studying 805 kids of 23 subtypes for ex vivo response to 18 cytotoxic/targeted drugs. Remarkable heterogeneity in ALL #pharmacotype across genomic landscape PGRN The Society for Functional Precision Medicine bit.ly/3VWuMtO

Proud of Shawn Lee and Wenjian for leading this massive collaboration with Dr. Bill Evans Mary Relling St. Jude Research

And we are actively recruiting motivated postdocs to work on this massive dataset, a lot to mine with new biology to follow up on. DM or email [email protected] if interested. St. Jude Research